Complete recovery following sudden sensorineural hearing loss in a patient with sickle cell disease

Salam Alkindi, Najwa Arafa, M. Al Okbi, Anil Pathare

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

A sickle cell disease (SCD) patient with vaso-occlusive crisis (VOC) developed sudden senserinural heari-ing loss (SNHL), which responded well to a rapid course of corticosteroids along with exchange transf-fusions. The otolaryngologist should be aware of the otologic manifestations of SCD such as SNHL. A good response to steroids, which averted a permanent hearing loss, warrants further studies to define the augmentive benefits of such therapy along with exchange transfusions in patients with SCD in VOC who develop sudden SNHL.

Original languageEnglish
Pages (from-to)97-99
Number of pages3
JournalHematology/ Oncology and Stem Cell Therapy
Volume4
Issue number2
DOIs
Publication statusPublished - 2011

Fingerprint

Sudden Hearing Loss
Sensorineural Hearing Loss
Sickle Cell Anemia
Hearing Loss
Adrenal Cortex Hormones
Steroids
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Complete recovery following sudden sensorineural hearing loss in a patient with sickle cell disease. / Alkindi, Salam; Arafa, Najwa; Al Okbi, M.; Pathare, Anil.

In: Hematology/ Oncology and Stem Cell Therapy, Vol. 4, No. 2, 2011, p. 97-99.

Research output: Contribution to journalArticle

@article{2e768d229d3f4ca5a39d7401e3d07b12,
title = "Complete recovery following sudden sensorineural hearing loss in a patient with sickle cell disease",
abstract = "A sickle cell disease (SCD) patient with vaso-occlusive crisis (VOC) developed sudden senserinural heari-ing loss (SNHL), which responded well to a rapid course of corticosteroids along with exchange transf-fusions. The otolaryngologist should be aware of the otologic manifestations of SCD such as SNHL. A good response to steroids, which averted a permanent hearing loss, warrants further studies to define the augmentive benefits of such therapy along with exchange transfusions in patients with SCD in VOC who develop sudden SNHL.",
author = "Salam Alkindi and Najwa Arafa and {Al Okbi}, M. and Anil Pathare",
year = "2011",
doi = "10.5144/1658-3876.2011.97",
language = "English",
volume = "4",
pages = "97--99",
journal = "Hematology/ Oncology and Stem Cell Therapy",
issn = "1658-3876",
publisher = "King Faisal Specialist Hospital and Research Centre",
number = "2",

}

TY - JOUR

T1 - Complete recovery following sudden sensorineural hearing loss in a patient with sickle cell disease

AU - Alkindi, Salam

AU - Arafa, Najwa

AU - Al Okbi, M.

AU - Pathare, Anil

PY - 2011

Y1 - 2011

N2 - A sickle cell disease (SCD) patient with vaso-occlusive crisis (VOC) developed sudden senserinural heari-ing loss (SNHL), which responded well to a rapid course of corticosteroids along with exchange transf-fusions. The otolaryngologist should be aware of the otologic manifestations of SCD such as SNHL. A good response to steroids, which averted a permanent hearing loss, warrants further studies to define the augmentive benefits of such therapy along with exchange transfusions in patients with SCD in VOC who develop sudden SNHL.

AB - A sickle cell disease (SCD) patient with vaso-occlusive crisis (VOC) developed sudden senserinural heari-ing loss (SNHL), which responded well to a rapid course of corticosteroids along with exchange transf-fusions. The otolaryngologist should be aware of the otologic manifestations of SCD such as SNHL. A good response to steroids, which averted a permanent hearing loss, warrants further studies to define the augmentive benefits of such therapy along with exchange transfusions in patients with SCD in VOC who develop sudden SNHL.

UR - http://www.scopus.com/inward/record.url?scp=79960997510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960997510&partnerID=8YFLogxK

U2 - 10.5144/1658-3876.2011.97

DO - 10.5144/1658-3876.2011.97

M3 - Article

C2 - 21727771

AN - SCOPUS:79960997510

VL - 4

SP - 97

EP - 99

JO - Hematology/ Oncology and Stem Cell Therapy

JF - Hematology/ Oncology and Stem Cell Therapy

SN - 1658-3876

IS - 2

ER -